Incidence, Natural History, and Risk Factors of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt With Polytetrafluoroethylene-Covered Stent Grafts

BACKGROUND AND AIMS:The aim of this study was to assess the incidence, natural history, and risk factors of hepatic encephalopathy (HE) after transjugular intrahepatic portosystemic shunt (TIPS) with the new polytetrafluoroethylene (PTFE)-covered stent grafts in cirrhotic patients.PATIENTS AND METHODS:Seventy-eight cirrhotic patients treated by TIPS with PTFE-covered stent grafts and followed by the same medical team—according to a prospective protocol for diagnostic workup and surveillance strategy—were reviewed. The follow-up was 19.9 ± 20.6 months.RESULTS: At least one episode of HE occurred in 35 of 78 (44.8%) patients. The probability of remaining free of HE was 53.8% (95% confidence interval [CI] 41.4–66.2] at 1 yr and 50.9% at 2 yr (95% CI 38.2–63.8%). The total number of HE episodes was 89. Fifty-five percent of the episodes were grades III–IV. The occurrence of HE tended to be constant during the follow-up, probably because of the very low incidence of shunt dysfunction (13.6% at 2 yr). Moreover, in six patients, a refractory HE required the reduction of the shunt diameter. One patient died due to variceal bleeding after this procedure. At a multivariate analysis, an older age, high creatinine levels, and low serum sodium and low albumin values were shown to be independent factors for the occurrence of HE. Serum creatinine level was the only variable related to the development of refractory HE at the logistic multivariate analysis.CONCLUSIONS: HE after TIPS with PTFE-covered stent grafts is frequent; its incidence is not confined to the first post-TIPS period, but it has the tendency to be frequent over time. Refractory HE occurred in 8% of patients and may be successfully managed by reducing the stent diameter. The selection of patients undergoing TIPS placement should be very accurate, especially for those subjects with abnormal creatinine level.

[1]  David R. Anderson,et al.  Model selection and multimodel inference : a practical information-theoretic approach , 2003 .

[2]  Franz Hackl,et al.  Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE‐covered stentgrafts versus bare stents , 2003, Hepatology.

[3]  Daniela Mapelli,et al.  Variability of Trail Making Test, Symbol Digit Test and Line Trait Test in normal people. A normative study taking into account age-dependent decline and sociobiological variables , 2002, Aging clinical and experimental research.

[4]  M. Hudson,et al.  Patency and reintervention rates during routine TIPSS surveillance , 1998, CardioVascular and Interventional Radiology.

[5]  O. Riggio,et al.  Polytetrafluoroethylene-covered nitinol stent-graft for transjugular intrahepatic portosystemic shunt creation: 3-year experience. , 2004, Radiology.

[6]  K. Reddy,et al.  The North American Study for the Treatment of Refractory Ascites. , 2003, Gastroenterology.

[7]  A. Freedman,et al.  Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: Results of a prospective controlled study , 1994, Hepatology.

[8]  M. Lafortune,et al.  Relationship between pre-TIPS liver perfusion by the portal vein and the incidence of post-TIPS chronic hepatic encephalopathy , 2001, American Journal of Gastroenterology.

[9]  H. Rousseau,et al.  Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long‐term results of a randomized multicentre study , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[10]  P. Hayes,et al.  Transjugular intrahepatic portosystemic stent shunt (TIPSS) modification in the management of post-TIPSS refractory hepatic encephalopathy , 2006, Gut.

[11]  T. Kroencke,et al.  Covered transjugular intrahepatic portosystemic stents maintain lower portal pressure and require fewer reinterventions than uncovered stents , 2004, Scandinavian journal of gastroenterology.

[12]  L. Seeff,et al.  Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. , 1977, Gastroenterology.

[13]  M. Merli,et al.  Polytetrafluoroethylene-Covered Stent Grafts for TIPS Procedure: 1-Year Patency and Clinical Results , 2004, American Journal of Gastroenterology.

[14]  A. Burroughs,et al.  Transjugular Intrahepatic Portosystemic Shunt versus Endoscopic Therapy: Randomized Trials for Secondary Prophylaxis of Variceal Bleeding: an Updated Meta-Analysis , 2002, Scandinavian journal of gastroenterology.

[15]  P. Kamath,et al.  A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts , 2000, Hepatology.

[16]  F. Nevens,et al.  Early and long-term clinical and radiological follow-up results of expanded-polytetrafluoroethylene-covered stent-grafts for transjugular intrahepatic portosystemic shunt procedures , 2004, European Radiology.

[17]  Niels Keiding,et al.  Statistical Models Based on Counting Processes , 1993 .

[18]  M. Maynar,et al.  Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. , 1996, Gastroenterology.

[19]  M. Morgan,et al.  Treatment for hepatic encephalopathy: tips from TIPS? , 2005, Journal of Hepatology.

[20]  A. Nicolini,et al.  Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites , 2004, Hepatology.

[21]  J. Rank,et al.  Development of stenoses in transjugular intrahepatic portosystemic shunts. , 1994, Radiology.

[22]  G. Passalacqua,et al.  TIPS with expanded polytetrafluoroethylene-covered stent: results of an Italian multicenter study. , 2005, AJR. American journal of roentgenology.

[23]  P. Hayes,et al.  Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage. , 1995, Journal of hepatology.

[24]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[25]  H. Rousseau,et al.  Preliminary results of a new expanded-polytetrafluoroethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt procedures. , 2002, AJR. American journal of roentgenology.

[26]  P. Hayes,et al.  Improved clinical outcome with transjugular intrahepatic portosystemic stent-shunt utilizing polytetrafluoroethylene-covered stents , 2006, European journal of gastroenterology & hepatology.

[27]  M. Peruggia.  Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach (2nd ed.) , 2003 .

[28]  P. Cole,et al.  Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. , 1996, Gastroenterology.

[29]  P. Kamath,et al.  Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis , 2002 .

[30]  R. Edwards,et al.  Results of a retrospective multicenter trial of the Viatorr expanded polytetrafluoroethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt creation. , 2004, Journal of vascular and interventional radiology : JVIR.

[31]  J. Lammer,et al.  Creation of transjugular intrahepatic portosystemic shunts with stent-grafts: initial experiences with a polytetrafluoroethylene-covered nitinol endoprosthesis. , 2001, Radiology.

[32]  V. Vilgrain,et al.  Transjugular intrahepatic portosystemic shunts: Comparison with paracentesis in patients with cirrhosis and refractory ascites: A randomized trial , 1996 .

[33]  C. Hildebolt,et al.  Encephalopathy after transjugular intrahepatic portosystemic shunting: analysis of incidence and potential risk factors. , 1997, AJR. American journal of roentgenology.

[34]  J. Roberts,et al.  Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. , 1995, The American journal of gastroenterology.

[35]  Maria Di Giovanni,et al.  Reliability of endoscopy in the assessment of variceal features: The Italian Liver Cirrhosis Project , 1987 .

[36]  C. Pinson,et al.  Incidence of shunt occlusion or stenosis following transjugular intrahepatic portosystemic shunt placement. , 1994, Gastroenterology.

[37]  H. Blum,et al.  Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding , 1997, The Lancet.

[38]  M. Merli,et al.  Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: A randomized multicenter trial , 1998 .

[39]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[40]  H. Rousseau,et al.  Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. , 2004, Gastroenterology.

[41]  C. Ripoll,et al.  Comparison of transjugular intrahepatic portosystemic shunt dysfunction in PTFE-covered stent-grafts versus bare stents. , 2005, European journal of radiology.

[42]  H. Figulla,et al.  Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Clinical, laboratory, psychometric, and electroencephalographic investigations , 1998, Hepatology.

[43]  E. Ring,et al.  Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients. , 1995, Gastroenterology.

[44]  M. Merli,et al.  Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. , 2005, Journal of hepatology.

[45]  P. Rossi,et al.  Use of a laryngeal mask in transjugular intrahepatic portosystemic shunt procedures. , 1998, Journal of vascular and interventional radiology : JVIR.

[46]  Eter,et al.  A COMPARISON OF PARACENTESIS AND TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTING IN PATIENTS WITH ASCITES , 2000 .